| abstract |
Disclosed are 2-(indol-5-yl)-1,1,1,3,3,3-hexafluoro-propan-2-ol derivatives as represented by formula (I), wherein A is an optionally substituted aryl or heterocyclic ring, and the other substituents are as defined herein. Also disclosed is the use of a therapeutically active substance as defined above for the preparation of medicaments for the prophylaxis and therapy of diseases which are modulated by LXR alpha and/or LXR beta agonists (diseases such as increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver. fibrosis of the liver, macular degeneration or Alzheimer's disease). |